Express News | Pliant Therapeutics Inc - Increased Authorized Size of Board From Ten to Eleven Members

ReutersJun 14 16:05 ET

Express News | Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

ReutersJun 13 16:05 ET

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Chohee Yun, M.D., the Company's newly appointed Senior Vice President of Clinical Development as a material inducement to her employment.

GlobeNewswireJun 12 16:05 ET

H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $36

H.C. Wainwright analyst Ed Arce maintains $Pliant Therapeutics(PLRX.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 40.0% an

moomoo NewsJun 7 06:32 ET · Ratings

Express News | Pliant Therapeutics To Present Data From Its Bexotegrast Program At The EASL International Liver Congress June 5-8, 2024

BenzingaJun 6 08:06 ET

Piper Sandler Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $40

Piper Sandler analyst Yasmeen Rahimi maintains $Pliant Therapeutics(PLRX.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 35.

moomoo NewsMay 23 07:33 ET